SOLICITATION NOTICE
R -- NeuroAIDS Therapeutic Initiative - Statement of Work
- Notice Date
- 1/8/2010
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- NOI-1403791
- Archive Date
- 2/2/2010
- Point of Contact
- Liem T Nguyen, Phone: 3014358780
- E-Mail Address
-
ln18x@nih.gov
(ln18x@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Statement of Work The National Institute of Health (NIH), National Institute on Drug Abuse (NIDA) on behalf of the National Institute of Mental Health (NIMH) seeks to procure professional service on a sole source basis with Dr. Deborah Ann Colosi, Bethesda, MD 20816. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority of FAR 13.106-1(b)(1) and FAR 13.501 (a)(1) to use Simplified Acquisition Procedure for commercial items. The North American Industry Classification System Code (NAICS) is 541990 and the business size standard is $7.0 million. Background NIMH Center for Mental Health Research on AIDS (CMHRA) supports the development of drugs to prevent or treat HIV disease of the nervous system disease. Efforts to expand NIMH's therapeutic research efforts as well as clinical trial approaches have been limited. Now that individuals are living longer with HIV, it is critical to identify a set of therapeutic strategies and potential drugs to better manage the complications of HIV infection of the nervous system. Therapeutic approaches have realized much success in managing HIV/AIDS; however strategies to prevent or treat the neurological complications that frequently accompany HIV disease have been less successful. This is due to limited availability of drugs across the blood brain barrier, the high degree of toxicity that accompanies long term use of current antiretroviral drugs, and the co-morbid mental health conditions that frequently accompany HIV/CNS disease, such as depression, anxieties, mood disorders, as well as others. The NIMH/CMHRA proposes to expand the therapeutics program by developing several initiatives to identify new therapeutic targets emerging from basic HIV neuropathogenesis research, and foster the pre-clinical and clinical testing of these drugs through mechanisms supportive of these approaches. Sole Source Justification Dr. Colosi has more than 5 years experience working in at Bayer HealthCare Pharmaceuticals. During that time, she participated in all aspects of the process of moving drugs from bench to bedside. This includes basic science research, planning and reviewing clinical trials, analyzing and summarizing results, and licensing issues. She has experience in developing and reviewing bioassays for drug efficacy, as well as biotechnology, including proteomic technologies. In addition, she has a strong background in basic science, including biochemistry and virology, as seen by her doctoral and post-doctoral research experience, which is essential to understand the complexities of targeting therapeutic interventions to HIV-mediated cell dysfunction. The CMHRA currently lacks this expertise in the drug development process and yet the need for a strong programmatic approach to therapeutics in NeuroAIDS is critical. Dr. Colosi has been researching the current state of therapeutic approaches to managing HIV/CNS disease over the past 6 months and has written an extensive review of this area. In addition, she has convened a meeting with some of the leaders in the field to review NIMH's current efforts and develop a set of recommendations for next steps. Given the extent of her knowledge and NIMH's intent to incorporate a therapeutics component is our program initiatives in the basic sciences, Dr. Colosi is uniquely positioned to move our proposed approaches to the next phase. Dr. Colosi brings scientific and drug-company expertise to this effort, which is currently not available among the program staff of the CMHRA. To make an award to a new and different contractor, it will delay the on-going study because the new contractor would have to spend an unacceptable amount of time to become familiar with the issues which have been defined by Dr. Colosi through previous work. In addition, a new contractor would not have the benefits of the frequent and extensive discussions that Dr. Colosi has had prior to and during the workshop that she convened. Dr. Colosi's previous work for NIMH has been outstanding and her continuation is critical to the development of this important program to improve the lives of individuals living with HIV. Therefore, it is determined that Dr. Colosi is uniquely qualified to perform the required service. No other sources can satisfy the agency's requirement. Scope of Work See attached Statement of Work Period of Performance is to be five (5) months from the award date, on or around February 1, 2010. Place of performance is Bethesda, Maryland. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can perform this requirement. Questions must be submitted in writing to the Contracting Officer, ln18x@nih.gov, no later than 2:00 PM January 14, 2010. Statement of capabilities must be submitted to ln18x@nih.gov on or before 3:00 PM Monday, January 18, 2010. It is the vendor's responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered in and have valid certifications in the Central Contractor Registration (CCR), www.ccr.gov and the Online Representations and Certifications Application (ORCA) www.orca.bpn.gov. Please reference announcement number 1403791 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/NOI-1403791/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02038677-W 20100110/100108235939-a103584649f560d78891a98c355f7969 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |